2- (6- ((2- (3- hydroxypropyl)- 5- methylphenylamino)methyl)- 2- (3- morpholin- 4- ylpropylamino)benzoimidazol- 1- ylmethyl)- 6- methylpyridin- 3- ol

inhibits respiratory syncytial virus fusion; structure in first source

Also Known As:

TMC 353121; TMC-353121; TMC353121

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - 2-(6-((2-(3-hydroxypropyl)-5-methylphenylamino)methyl)-2-(3-morpholin-4-ylpropylamino)benzoimidazol-1-ylmethyl)-6-methylpyridin-3-ol: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - 2-(6-((2-(3-hydroxypropyl)-5-methylphenylamino)methyl)-2-(3-morpholin-4-ylpropylamino)benzoimidazol-1-ylmethyl)-6-methylpyridin-3-ol: 2

Experts

1.	Andries, Koen: 1 article (01/2015)
2.	Bonfanti, Jean-François: 1 article (01/2015)
3.	De Jonghe, Sandra: 1 article (01/2015)
4.	Ispas, Gabriela: 1 article (01/2015)
5.	Koul, Anil: 1 article (01/2015)
6.	Rouan, Marie-Claude: 1 article (01/2015)
7.	Roymans, Dirk: 1 article (01/2015)
8.	Sanders-Beer, Brigitte: 1 article (01/2015)
9.	Sheehan, Jennifer: 1 article (01/2015)
10.	Simmen, Kenneth: 1 article (01/2015)

Related Diseases

1.	Infections 01/01/2015 - "Study 1 evaluated the prophylactic and therapeutic efficacy of TMC353121 at a target plasma level of 50 ng/mL (n=15; Group 1: prophylactic arm [Px50], 0.033 mg/mL TMC353121, flow rate 2.5 mL/kg/h from 24 hours pre-infection to 10 days; Group 2: therapeutic arm [Tx50], 0.033 mg/mL TMC353121 from 24 hours postinfection to 8 days; Group 3: control [Vh1] vehicle, 24 hours post-infection to 8 days). " 01/01/2015 - "Study 2 evaluated the prophylactic efficacy of TMC353121 at target plasma levels of 5 and 500 ng/mL (n=12; Group 1: prophylactic 5 arm [Px5], 0.0033 mg/mL TMC353121, flow rate 2.5 mL/kg/h from 72 hours pre-infection to 14 days; Group 2: prophylactic 500 arm [Px500], 0.33 mg/mL TMC353121; Group 3: control [Vh2] vehicle, 14 days). " 08/01/2011 - "At doses of 0.25-10 mg · kg(-1), TMC353121 significantly reduced viral load, bronchoalveolar lavage cell accumulation and the severity of lung histopathological change after infection. " 08/01/2011 - "The drug is a small molecule (TMC353121) discovered by screening for fusion inhibitory properties against RSV in a cellular infection model. "
2.	Respiratory Syncytial Virus Infections 08/01/2011 - "The pharmacokinetics of TMC353121 was studied in BALB/c mice and antiviral effects determined by testing viral loads in lung tissue by quantitative RT-PCR and plaque assay after intranasal RSV infection. "
3.	Pneumonia (Pneumonitis) 08/01/2011 - "Therefore, TMC353121 is a novel potent antiviral drug, in vivo reducing RSV replication and inhibiting consequential lung inflammation, with a great potential for further clinical development."

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)